Search Results

Amid heightened public concern, the cost of prescription drugs is a focus of attention by the Biden administration and lawmakers in Congress and state capitals. Proposed actions range from allowing Medicare to negotiate the prices of certain drugs to limiting some drug price increases to inflation and capping out of pocket costs for Medicare beneficiaries in Part D, among other initiatives. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.

Featured Prescription Drugs Resources

How Would the Prescription Drug Provisions in the Senate Reconciliation Proposal Affect Medicare Beneficiaries? July 27, 2022 Issue Brief

The brief provides a quick explainer of the prescription drug provisions in legislative text released by the Senate Finance Committee to be included in a forthcoming reconciliation bill and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.

Related Prescription Drugs Resources

Prices Increased Faster Than Inflation for Half of all Drugs Covered by Medicare in 2020
Out-of-pocket spending on insulin among people with private insurance
How Do Prescription Drug Costs in the United States Compare to Other Countries?
Public Opinion on Prescription Drugs and Their Prices
Insulin Costs and Coverage in Medicare Part D
Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act
The Public Weighs In On Medicare Drug Negotiations
Potential Savings for Medicare Part D Enrollees Under Proposals to Add a Hard Cap on Out-of-Pocket Spending
Medicare Part B Drugs: Cost Implications for Beneficiaries in Traditional Medicare and Medicare Advantage
10 FAQs on Prescription Drug Importation
Medicaid Outpatient Prescription Drug Trends During the COVID-19 Pandemic
Prescription Drug Rebates, Explained

Insulin Out-of-Pocket Costs in Medicare Part D July 28, 2022 Issue Brief

Addressing the cost of insulin continues to be at the forefront of policy discussions around prescription drugs. This analysis describes out-of-pocket spending on insulin products by Medicare beneficiaries enrolled in Part D drug plans, along with state-level use and spending data.

Understanding the Effects of Direct-to-Consumer Prescription Drug Advertising

Featured Prescription Drugs Resources

Related Prescription Drugs Resources

Refine Results

Results